297 related articles for article (PubMed ID: 26535615)
1. Docetaxel for the treatment of bladder cancer.
Albany C; Sonpavde G
Expert Opin Investig Drugs; 2015; 24(12):1657-64. PubMed ID: 26535615
[TBL] [Abstract][Full Text] [Related]
2. Emerging drugs for urothelial (bladder) cancer.
Cumberbatch K; He T; Thorogood Z; Gartrell BA
Expert Opin Emerg Drugs; 2017 Jun; 22(2):149-164. PubMed ID: 28556678
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of capecitabine with or without docetaxel therapy for the treatment of patients with advanced urothelial carcinoma: a single-institution experience.
Xue C; An X; Cao Y; Chen T; Yang W; Deng Y; Han H; Teng X; Zhou F; Shi Y
Oncotarget; 2016 Sep; 7(39):63722-63729. PubMed ID: 27577082
[TBL] [Abstract][Full Text] [Related]
4. Clinical evidence for the first-line treatment of advanced urothelial carcinoma: Current paradigms and emerging treatment options.
Koufopoulou M; Miranda PAP; Kazmierska P; Deshpande S; Gaitonde P
Cancer Treat Rev; 2020 Sep; 89():102072. PubMed ID: 32769039
[TBL] [Abstract][Full Text] [Related]
5. Schedule dependent efficacy of gefitinib and docetaxel for bladder cancer.
Kassouf W; Luongo T; Brown G; Adam L; Dinney CP
J Urol; 2006 Aug; 176(2):787-92. PubMed ID: 16813948
[TBL] [Abstract][Full Text] [Related]
6. Emerging first line treatment options for bladder cancer: a review of phase II and III therapies in the pipeline.
Jamy O; Sonpavde G
Expert Opin Emerg Drugs; 2017 Dec; 22(4):347-355. PubMed ID: 29226734
[TBL] [Abstract][Full Text] [Related]
7. Concurrent platinum and docetaxel chemotherapy and external radical radiotherapy in patients with invasive transitional cell bladder carcinoma. A preliminary report of tolerance and local control.
Varveris H; Delakas D; Anezinis P; Haldeopoulos D; Mazonakis M; Damilakis J; Metaxaris G; Chondros N; Mavromanolakis E; Daskalopoulos G; Dimitrakopoulos A; Kranidis A
Anticancer Res; 1997; 17(6D):4771-80. PubMed ID: 9494605
[TBL] [Abstract][Full Text] [Related]
8. Do patients with metastatic urothelial carcinoma benefit from docetaxel as second-line chemotherapy?
Morales-Barrera R; Suárez C; Valverde C; Nuñez I; Maldonado X; Morote J; Carles J
Clin Transl Oncol; 2014 Jan; 16(1):102-6. PubMed ID: 23606355
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic drug evaluation of atezolizumab for the treatment of locally advanced or metastatic urothelial carcinoma.
Patel R; Bock M; Polotti CF; Elsamra S
Expert Opin Drug Metab Toxicol; 2017 Feb; 13(2):225-232. PubMed ID: 28043166
[TBL] [Abstract][Full Text] [Related]
10. Patient eligibility and trial design for the salvage therapy of advanced urothelial carcinoma.
Sonpavde G; Bellmunt J; Rosenberg JE; Regazzi AM; Bajorin DF; Choueiri TK; Qu AQ; Niegisch G; Albers P; Necchi A; Di Lorenzo G; Fougeray R; Wong YN; Sridhar SS; Ko YJ; Milowsky MI; Galsky MD; Pond GR
Clin Genitourin Cancer; 2014 Dec; 12(6):395-8. PubMed ID: 25035282
[No Abstract] [Full Text] [Related]
11. Atezolizumab in invasive and metastatic urothelial carcinoma.
Crist M; Balar A
Expert Rev Clin Pharmacol; 2017 Dec; 10(12):1295-1301. PubMed ID: 28994323
[TBL] [Abstract][Full Text] [Related]
12. Molecular biology and targeted therapies for urothelial carcinoma.
Seront E; Machiels JP
Cancer Treat Rev; 2015 Apr; 41(4):341-53. PubMed ID: 25828962
[TBL] [Abstract][Full Text] [Related]
13. State-of-the-art management of metastatic disease at initial presentation or recurrence.
Calabrò F; Sternberg CN
World J Urol; 2006 Nov; 24(5):543-56. PubMed ID: 17031652
[TBL] [Abstract][Full Text] [Related]
14. A Review of Immune Checkpoint Inhibitors for the Management of Locally Advanced or Metastatic Urothelial Carcinoma.
Hanna KS
Pharmacotherapy; 2017 Nov; 37(11):1391-1405. PubMed ID: 28950037
[TBL] [Abstract][Full Text] [Related]
15. Second-line systemic therapy for metastatic urothelial carcinoma of the bladder.
Ortmann CA; Mazhar D
Future Oncol; 2013 Nov; 9(11):1637-51. PubMed ID: 24156324
[TBL] [Abstract][Full Text] [Related]
16. Avelumab for the treatment of urothelial cancer.
Rodriguez-Vida A; Bellmunt J
Expert Rev Anticancer Ther; 2018 May; 18(5):421-429. PubMed ID: 29540084
[TBL] [Abstract][Full Text] [Related]
17. Systemic treatments for metastatic urothelial carcinoma.
Lalani AA; Sonpavde GP
Expert Opin Pharmacother; 2019 Feb; 20(2):201-208. PubMed ID: 30412003
[TBL] [Abstract][Full Text] [Related]
18. Phase I trial of intravesical docetaxel in the management of superficial bladder cancer refractory to standard intravesical therapy.
McKiernan JM; Masson P; Murphy AM; Goetzl M; Olsson CA; Petrylak DP; Desai M; Benson MC
J Clin Oncol; 2006 Jul; 24(19):3075-80. PubMed ID: 16809732
[TBL] [Abstract][Full Text] [Related]
19. Prospects and progress of immunotherapy for bladder cancer.
Boegemann M; Aydin AM; Bagrodia A; Krabbe LM
Expert Opin Biol Ther; 2017 Nov; 17(11):1417-1431. PubMed ID: 28832261
[TBL] [Abstract][Full Text] [Related]
20. Durvalumab in urothelial cancers.
Lavaud P; Hamilou Z; Loriot Y; Massard C
Expert Rev Anticancer Ther; 2018 Apr; 18(4):311-318. PubMed ID: 29486607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
